BRCA1 and ovarian carcinoma: It also allows for subsequent implementation of risk-reducing and/or early detection strategies; for example, BRCA1/2 PV carriers have an increased risk of developing contralateral breast cancer (40% for BRCA1 and 26% for BRCA2 at 20 years after initial diagnosis) [10] and ovarian cancer (lifetime risk of 44% for BRCA1 and 17% BRCA2) [10].